From other board...
betasplen2 hours ago
The Exo Restore for stroke victims will be launching in Europe in a couple of months (pending CE approval which should be almost a given) and in early 3Q if the FDA approves for use in the US. They have several units awaiting insurance approval and with the recent change in Cigna's policy, they should be winning a good % of them. Same with the VA as the training has been completed for the veterans. They have reduced cash burn significantly in 2018 and said they will do even better this year. With the cash in hand, they can hit the ground running with order fulfillment. The Restore is only $12K (vs $100K for the current device). The market is huge with 750K stroke victims in the US alone. Do the math - that is $9B in market potential! I think they can conservatively do $25M in sales this year. Currently, they are trading at only a $18M market cap. I think this can get to $15 by Christmas ($72M) and easily over $50 ($200M) next year if Restore sells as expected...
betasplen2 hours ago
The Exo Restore for stroke victims will be launching in Europe in a couple of months (pending CE approval which should be almost a given) and in early 3Q if the FDA approves for use in the US. They have several units awaiting insurance approval and with the recent change in Cigna's policy, they should be winning a good % of them. Same with the VA as the training has been completed for the veterans. They have reduced cash burn significantly in 2018 and said they will do even better this year. With the cash in hand, they can hit the ground running with order fulfillment. The Restore is only $12K (vs $100K for the current device). The market is huge with 750K stroke victims in the US alone. Do the math - that is $9B in market potential! I think they can conservatively do $25M in sales this year. Currently, they are trading at only a $18M market cap. I think this can get to $15 by Christmas ($72M) and easily over $50 ($200M) next year if Restore sells as expected...
